Alzheimer Disease & Dementias
Articles 161-176 of 407
- Medical NewsBuntanetap Safe With Signals of Efficacy for Alzheimer Disease and Phase 3 Trials Are Being Initiated
In a phase 2 trial (NCT04524351) in people with early Alzheimer disease (AD) or Parkinson disease (PD) treatment with 5 to 80 mg/day oral buntanetap (ANVS401; Annovis, Berwyn, PA) for 25±2 days had no adverse events. These results are consistent with the ascending dose study in which side effects di...
08/08/2022 - Medical NewsFosgonimeton Well Tolerated With Possible Benefits for Alzheimer Disease in the Absence of Cholinergic Treatment
In the phase 2 ACT-AD trial (NCT04491006), fosgonimeton (Athira Pharma, Bothell, WA) was well-tolerated, and no serious adverse events (AEs ) occurred. Mild-to-moderate AEs occurred in 89% (24/27) and 100% (26/26), respectively, with 40 or 70 mg/day fosgonimeton and 70% with placebo (17/24). The ov...
08/03/2022 - Medical NewsTransdermal Donepezil Provides Drug Delivery Equivalent to Oral Donezepil With Favorable GI Side Effect Profile
Results from a phase 1 trial (NCT04617782) show that both strengths of a donepezil transdermal system (Adlarity; Corium, Boston, MA) maintain equivalent daily exposure of donepezil compared to oral formulations of the drug and have a favorable gastrointestinal (GI) side effect profile.
The therapy...
08/03/2022 - Medical NewsPhyscial Exercise May Stall Cognitive Decline in Mild Cognitive Impairment
In the phase 3 EXERT trial (NCT02814526), 296 individuals, age 65 to 89, with amnestic mild cognitive impairment (MCI) who participated in supervised exercise programs maintained baseline cognitive abilities. Cognition was measured at baseline and after 12 months of supervised exercise with the Alzh...
08/02/2022 - Medical NewsPreliminary Trial Results Suggest Benefit of Targeting Glucose and Lipid Metabolism for Treatment of Alzheimer’s Disease
Preliminary data have been shared from the PIONEER study (NCT04251182) of a peroxisome proliferator-activated nuclear receptor δ/γ (PPAR δ/γ) agonist (T3D-959; Research Triangle Park, NC), which regulates glucose and lipid metabolism. The trial is at 92% enrollment and participants have mild-to-mode...
08/02/2022 - Medical NewsAducanumab Appropriate Use for Alzheimer Disease Treatment Recommendations Updated
An update to appropriate clinical use of aducanumab (Aduhelm; Biogen, Cambridge, MA and Eisai, Woodcliff Lake, NJ) for treatment of Alzheimer disease (AD) was published in the Journal of Prevention of Alzheimer's Disease and presented in a panel discussion at the Alzheimer Association International ...
08/02/2022 - Medical NewsLoss of Smell May Predict Alzheimer Disease and Dementia
The loss of sense of smell is known to be associated with cognitive decline but has also been shown to predict brain atrophy associated with Alzheimer disease (AD) and dementia. New findings published in Alzheimer’s & Dementia suggests that smell-test screening could be developed to predict cognitiv...
07/29/2022